宫颈大细胞神经内分泌癌诊治进展

doi:10.12280/gjfckx.20230266

摘要/Abstract

摘要：

宫颈大细胞神经内分泌癌（large cell neuroendocrine carcinoma，LCNEC）是一种特殊类型的宫颈癌，具有恶性程度高、侵袭性强等特征，早期即表现出全身转移倾向。宫颈LCNEC的发病与高危型HPV感染密切相关，因临床表现缺乏特异性，对其的诊断主要依靠典型的病理学特征及特异性神经内分泌标志物的检测。由于宫颈LCNEC的发病率低，病例资料有限，目前尚无标准化的诊疗方案，对其治疗主要借鉴于小细胞肺癌，以根治性手术联合化疗及放疗为主。但基因组数据表明，宫颈LCNEC在遗传学上与常见的宫颈癌类型更相似，而不是肺或膀胱等的宫颈外的小细胞神经内分泌癌，这对一些因肿瘤组织间具有相似形态学表现而采取相似治疗方案的思路提出了质疑。综述宫颈LCNEC的最新研究进展，以期为临床工作提供参考。

关键词: 宫颈肿瘤, 癌, 大细胞, 癌, 神经内分泌, 诊断, 治疗

Abstract:

Cervical large cell neuroendocrine carcinoma (LCNEC) is a special type of cervical cancer with characteristics of high malignancy and aggressiveness, and shows a tendency to metastasize systemically at an early stage. The development of cervical LCNEC is closely related to high-risk HPV infection. The diagnosis of cervical LCNEC is mainly based on typical pathological features and detection of specific neuroendocrine markers because of the lack of specificity of clinical manifestations. Due to the low incidence of cervical LCNEC and limited case data, there is no standardized treatment protocol, and its treatment is mainly based on small cell lung cancer, with radical surgery combined with chemotherapy and radiotherapy. However, genomic data suggest that cervical LCNEC is genetically more similar to common types of cervical cancer rather than to small cell neuroendocrine carcinoma outside the cervix, such as lung or bladder, which questions the ideas of adopting similar treatment regimens because of similar morphological manifestations among tumor tissues. This article focuses on a review of recent research advances regarding cervical LCNEC, with the aim of providing references and lessons for clinical work.

Key words: Uterine cervical neoplasms, Carcinoma, large cell, Carcinoma, neuroendocrine, Diagnosis, Therapy

席玲, 周顺卿, 韩丽英. 宫颈大细胞神经内分泌癌诊治进展[J]. 国际妇产科学杂志, 2023, 50(4): 372-376.

XI Ling, ZHOU Shun-qing, HAN Li-ying. Progress in Diagnosis and Treatment of Cervical Large Cell Neuroendocrine Carcinoma[J]. Journal of International Obstetrics and Gynecology, 2023, 50(4): 372-376.

参考文献 36

[1]	Lee E, Ji YI. Large Cell Neuroendocrine Carcinoma of the Cervix with Sequential Metastasis to Different Sites: A Case Report[J]. Case Rep Oncol, 2018, 11(3):665-670. doi: 10.1159/000493912. doi: 10.1159/000493912 pmid: 30483095
[2]	Caruso G, Sassu CM, Tomao F, et al. The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions[J]. Crit Rev Oncol Hematol, 2021, 162:103344. doi: 10.1016/j.critrevonc.2021.103344. doi: 10.1016/j.critrevonc.2021.103344
[3]	Grayson W, Rhemtula HA, Taylor LF, et al. Detection of human papillomavirus in large cell neuroendocrine carcinoma of the uterine cervix: a study of 12 cases[J]. J Clin Pathol, 2002, 55(2):108-114. doi: 10.1136/jcp.55.2.108. doi: 10.1136/jcp.55.2.108 pmid: 11865004
[4]	Salvo G, Gonzalez Martin A, Gonzales NR, et al. Updates and management algorithm for neuroendocrine tumors of the uterine cervix[J]. Int J Gynecol Cancer, 2019, 29(6):986-995. doi: 10.1136/ijgc-2019-000504. doi: 10.1136/ijgc-2019-000504 pmid: 31263021
[5]	Takayanagi D, Hirose S, Kuno I, et al. Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix[J]. Cancers (Basel), 2021, 13(6):1215. doi: 10.3390/cancers13061215. doi: 10.3390/cancers13061215
[6]	Burkeen G, Chauhan A, Agrawal R, et al. Gynecologic large cell neuroendocrine carcinoma: A review[J]. Rare Tumors, 2020, 12:2036361320968401. doi: 10.1177/2036361320968401. doi: 10.1177/2036361320968401
[7]	Hillman RT, Cardnell R, Fujimoto J, et al. Comparative genomics of high grade neuroendocrine carcinoma of the cervix[J]. PLoS One, 2020, 15(6):e0234505. doi: 10.1371/journal.pone.0234505. doi: 10.1371/journal.pone.0234505
[8]	Uccella S, La Rosa S, Metovic J, et al. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features(G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites[J]. Endocr Pathol, 2021, 32(1):192-210. doi: 10.1007/s12022-020-09660-z. doi: 10.1007/s12022-020-09660-z pmid: 33433884
[9]	Saghaeiannejad Esfahani H, Vela CM, Chauhan A. Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma[J]. Front Oncol, 2021, 11:653153. doi: 10.3389/fonc.2021.653153. doi: 10.3389/fonc.2021.653153
[10]	Ordulu Z, Mino-Kenudson M, Young RH, et al. Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases[J]. Am J Surg Pathol, 2022, 46(12):1670-1681. doi: 10.1097/PAS.0000000000001943. doi: 10.1097/PAS.0000000000001943 pmid: 36069807
[11]	Eskander RN, Elvin J, Gay L, et al. Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms[J]. JCO Precis Oncol, 2020 Sep 3;4:PO.19.00248. doi: 10.1200/PO.19.00248. doi: 10.1200/PO.19.00248
[12]	Mahdi H, Joehlin-Price A, Elishaev E, et al. Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities[J]. Mol Oncol, 2021, 15(12):3545-3558. doi: 10.1002/1878-0261.13057. doi: 10.1002/1878-0261.13057 pmid: 34245124
[13]	Albores-Saavedra J, Martinez-Benitez B, Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis[J]. Int J Gynecol Pathol, 2008, 27(3):333-339. doi: 10.1097/PGP.0b013e31815de006. doi: 10.1097/PGP.0b013e31815de006 pmid: 18580310
[14]	Wang M, Vasey Q, Varikatt W, et al. Ectopic insulin secretion by a large-cell neuroendocrine carcinoma of the cervix[J]. Clin Case Rep, 2021, 9(1):482-486. doi: 10.1002/ccr3.3562. doi: 10.1002/ccr3.3562
[15]	Le DT, Do KH, Do TA, et al. Combined Large-Cell Neuroendocrine and Squamous Cell Carcinoma of the Uterine Cervix with a Personal History of the Primary Breast Duct Carcinoma in situ: A Clinicopathological Characteristic and Outcome[J]. Case Rep Oncol, 2022, 15(2):770-775. doi: 10.1159/000526337. doi: 10.1159/000526337 pmid: 36157693
[16]	Georgescu TA, Bohiltea RE, Munteanu O, et al. Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract[J]. Medicina (Kaunas), 2021, 57(12):1338. doi: 10.3390/medicina57121338. doi: 10.3390/medicina57121338
[17]	Yasuoka H, Tsujimoto M, Ueda M, et al. Monoclonality of composite large-cell neuroendocrine carcinoma and invasive intestinal-type mucinous adenocarcinoma of the cervix: a case study[J]. Int J Gynecol Pathol, 2013, 32(4):416-420. doi: 10.1097/PGP.0b013e3 18261c35b. doi: 10.1097/PGP.0b013e318261c35b pmid: 23722515
[18]	Erdem BE, Çiğdem V, Şener G, et al. Smear cytological features of large cell neuroendocrine carcinoma of the uterine cervix in pregnancy: A case report and review of the literature[J]. Diagn Cytopathol, 2019, 47(2):137-141. doi: 10.1002/dc.24106. doi: 10.1002/dc.24106 pmid: 30461217
[19]	Sarfraz H, Syal S, Sarfraz S, et al. Large Cell Neuroendocrine Cervical Carcinoma: A Case Report[J]. Cureus, 2020, 12(1):e6544. doi: 10.7759/cureus.6544. doi: 10.7759/cureus.6544
[20]	Prodromidou A, Phelps DL, Pergialiotis V, et al. Clinicopathological characteristics and survival outcomes of patients with large cell neuroendocrine carcinoma of the uterine cervix: A systematic review and meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2022, 270:212-220. doi: 10.1016/j.ejogrb.2022.01.014. doi: 10.1016/j.ejogrb.2022.01.014 pmid: 35093830
[21]	Tempfer CB, Tischoff I, Dogan A, et al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature[J]. BMC Cancer, 2018, 18(1):530. doi: 10.1186/s12885-018-4447-x. doi: 10.1186/s12885-018-4447-x pmid: 29728073
[22]	Ting CH, Wang TY, Wu PS. Insulinoma-associated Protein 1 Expression and Its Diagnostic Significance in Female Genital Tract Neuroendocrine Carcinomas[J]. Int J Gynecol Pathol, 2021, 40(5):452-459. doi: 10.1097/PGP.0000000000000722. doi: 10.1097/PGP.0000000000000722
[23]	Castelnau-Marchand P, Pautier P, Genestie C, et al. Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience[J]. Int J Gynecol Cancer, 2018, 28(5):1013-1019. doi: 10.1097/IGC.0000000000001242. doi: 10.1097/IGC.0000000000001242 pmid: 29595759
[24]	刘倩倩, 汪洋, 马安娜, 等. 宫颈神经内分泌癌的预后因素[J]. 分子影像学杂志, 2021, 44(6):1017-1023. doi: 10.12122/j.issn.1674-4500.2021.06.27. doi: 10.12122/j.issn.1674-4500.2021.06.27
[25]	Ishikawa M, Kasamatsu T, Tsuda H, et al. A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: Prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes[J]. Gynecol Oncol, 2019, 155(3):444-451. doi: 10.1016/j.ygyno.2019.09.018. doi: S0090-8258(19)31540-9 pmid: 31635755
[26]	Stecklein SR, Jhingran A, Burzawa J, et al. Patterns of recurrence and survival in neuroendocrine cervical cancer[J]. Gynecol Oncol, 2016, 143(3):552-557. doi: 10.1016/j.ygyno.2016.09.011. doi: S0090-8258(16)31409-3 pmid: 27645621
[27]	Xie S, Song L, Yang F, et al. Enhanced efficacy of adjuvant chemotherapy and radiotherapy in selected cases of surgically resected neuroendocrine carcinoma of the uterine cervix: A retrospective cohort study[J]. Medicine (Baltimore), 2017, 96(11):e6361. doi: 10.1097/MD.0000000000006361. doi: 10.1097/MD.0000000000006361
[28]	Robin TP, Amini A, Schefter TE, et al. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy[J]. Brachytherapy, 2016, 15(6):845-850. doi: 10.1016/j.brachy.2016.08.007. doi: S1538-4721(16)30536-0 pmid: 27720204
[29]	Yu L, Suye S, Huang R, et al. Expression and clinical significance of a new neuroendocrine marker secretagogin in cervical neuroendocrine carcinoma[J]. J Clin Pathol, 2021, 74(12):787-795. doi: 10.1136/jclinpath-2020-206889. doi: 10.1136/jclinpath-2020-206889 pmid: 33060116
[30]	Tangjitgamol S, Ramirez PT, Sun CC, et al. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study[J]. Int J Gynecol Cancer, 2005, 15(4):646-656. doi: 10.1111/j.1525-1438. 2005.00121.x. doi: 10.1111/j.1525-1438. 2005.00121.x pmid: 16014119
[31]	Gadducci A, Carinelli S, Aletti G. Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists[J]. Gynecol Oncol, 2017, 144(3):637-646. doi: 10.1016/j.ygyno.2016. 12.003. doi: S0090-8258(16)31621-3 pmid: 28057354
[32]	戴戈扬, 陈高文, 李肖璇, 等. 罕见宫颈大细胞神经内分泌癌患者的维持妊娠与母婴管理[J]. 南方医科大学学报, 2021, 41(1):1-9. doi: 10.12122/j.issn.1673-4254.2021.01.01. doi: 10.12122/j.issn.1673-4254.2021.01.01
[33]	Gil-Ibañez B, Regueiro P, Llurba E, et al. Challenges in the management of neuroendocrine cervical cancer during pregnancy: A case report[J]. Mol Clin Oncol, 2018, 9(5):519-522. doi: 10.3892/mco.2018.1717. doi: 10.3892/mco.2018.1717 pmid: 30402233
[34]	Bos L, Goulder A, Prescott L, et al. Isolated subcutaneous recurrence of high-grade neuroendocrine tumor of the cervix[J]. Gynecol Oncol Rep, 2021, 37:100780. doi: 10.1016/j.gore.2021.100780. doi: 10.1016/j.gore.2021.100780
[35]	张师前, 屈庆喜, 林仲秋. 子宫颈神经内分泌癌诊断与治疗专家指导意见(2022年版)[J]. 中国实用妇科与产科杂志, 2022, 38(2):170-176. doi: 10.19538/j.fk2022020111. doi: 10.19538/j.fk2022020111
[36]	Cimic A, Vranic S, Arguello D, et al. Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix[J]. Appl Immunohistochem Mol Morphol, 2021, 29(4):299-304. doi: 10.1097/PAI.0000000000000884. doi: 10.1097/PAI.0000000000000884